Efficacy and safety of sitagliptin as add-on therapy to multiple daily insulin injections therapy in inadequately controlled Japanese subjects with type 2 diabetes

Efficacy and safety of sitagliptin as add-on therapy to multiple daily insulin injections therapy in inadequately controlled Japanese subjects with type 2 diabetes - Combination therapy with MDI and DPP4i

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010157

Enrollment

Registered

2013-03-11

Start date

2013-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

50mg/day sitagliptin 24 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetes treated with MDI at dose of at least 10 units/day and for at least 12 months HbA1c>6.9%

Exclusion criteria

Exclusion criteria: type 1 diabetes

Design outcomes

Primary

Measure	Time frame
HbA1c, hypoglycemia	—

Secondary

Measure	Time frame
1,5-anhydroglucitol (1,5-AG), body mass index (BMI), insulin doses, adverse events	—

Countries

Japan

Contacts

Public ContactSeiya Shimoda

Faculty of Life Sciences, Kumamoto University Department of Metabolic Medicine

sshimoda@gpo.kumamoto-u.ac.jp096-373-5169

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026